Hall A, September 8, 2014

Transkript

Hall A, September 8, 2014
2
3
Hall A, September 8, 2014
4
08:00-08:30
Registration
08:30-09:00
Opening Ceremony
09:00-09:45
A unifying PKPD relationship and its application in selecting the dose and dosing interval for a new nanoparticulate formulation
Leslie Z. Benet - Plenary Lecture, University of California San Francisco, United States
09:45-10:15
Emerging concepts in dendrimer-based nanomedicine: translation to clinical applications.
Donald A. Tomalia, Virginia Commonwealth University, United States
10:15-10:45
Non-biological complex drugs and nanosimilars: complexity is in the details
Gerrit Borchard, University of Geneva, Switzerland
10:45-11:00
Coffee Break
11:00-11:30
An oral nano/microparticulate delivery system promotes intestinal absorption of drug loaded nanocapsules
Simon Benita, The Hebrew University of Jerusalem, Israel
11:30-12:00
Nanoscale drug delivery systems and the blood-brain barrier
Yılmaz Çapan, Hacettepe University, Turkey
12:00-12:30
Nanotechnology innovations for neurological disorders
Sayed Moien Moghimi, University of Copenhagen, Denmark
12:30-14:00
Lunch
14:00-14:30
Nanotechnologies for lung delivery: efficacy and safety
Elias Fattal, University of Paris-Sud, France
14:30-15:00
Nanoparticles for targeting ocular and renal tissue
Achim Goepferich, University of Regensburg, Germany
15:00-15:30
Nanoenabled medicines cross challenging biological barriers
Ijeoma F. Uchegbu, UCL School of Pharmacy, United Kingdom
15:30-16:00
Self assembly strategy for preparation of core-shell nanoparticles as anticancer drug carrier systems
Katerina Goracinova, University “Sts Cyril and Methodius”, Macedonia
16:00-16:15
Coffee Break
16:15-16:45
Cationic coated nanoparticles for intravenous or oral administration in cancer chemotherapy
Erem Bilensoy, Hacettepe University, Turkey
16:45-17:15
BASF Oleochemicals/ Improving Patient Compliance
Cihan Sancaktaroğlu, BASF, Turkey
17:15-17:45
Formulation considerations for push/pull osmotic pumps
Marcel Cimpan, Colorcon, United Kingdom
17:45-18:00
Oral Presentation-1
18:00-18:15
Oral Presentation-2
18:15-18:30
Oral Presenttaion-3
Hall B, September 8, 2014
14:00-14:30
Title to be announced
Saim Kerman, Turkish Medicines and Medical Devices Agency – TİTCK, Turkey
14:30-15:00
Title to be announced
SGK Speaker, Republic of Turkey Social Security Institution - SGK, Turkey
15:00-15:30
The impact of pharmaceutical reimbursement decisions on health indicators and health care services: Examples from Turkey
and abroad
Mehtap Tatar, Hacettepe University, Turkey
15:30-16:00
Pharmaceutical reimbursement system in Turkey: What has been done and what must be done in the future?
Bülent Gümüşel, Hacettepe University, Turkey
16:00-16:20
Coffee Break
16:20-16:50
Future of access to medicines: for reimbursed and self-pay
Abdulkadir Keskinaslan, Novartis, Switzerland / University of Washington, United States
16:50-17:10
New Approaches to Asset Pricing Models from the point of view of Decision Makers & Industry
Osman Kara, Association of Research-Based Pharmaceutical Companies – AİFD, Turkey
17:10-17:30
Current status and experienced problems of pharmaceutical reimbursement
Ecz. Tunç Köksal, Pharmaceutical Manufacturers Association of Turkey – İEİS, Turkey
17:30-17:50
Pharmaceutical reimbursement systems and view of a pharmacist
Harun Kızılay, Turkish Pharmacists’ Association – TEB, Turkey
17:50-18:30
Panel Discussion
5
Hall A, September 9, 2014
6
08:30-09:15
Opportunities and challenges for design and development of anticancer nanomedicines
Ruth Duncan-Plenary Lecture, Cardiff University, United Kingdom
09:15-09:45
Opportunities offered by nanotechnology in topical drug delivery
Carla Caramella, University of Pavia, Italy
09:45-10:15
Physicochemical characteristics of polymer based drug delivery systems: the influence on formulation process and on drug
release
Sasa Baumgartner, University of Ljubljana, Slovenia
10:15-10:45
Targeting nanomedicines to epithelial barriers - intestines, skin and lung
Claus-Michael Lehr, Saarland University, Germany
10:45-11:00
Coffee Break
11:00-11:30
Recent nano medical system developed with PLGA nano particulate platform
Yoshiaki Kawashima, Aichi Gakuin University, Japan
11:30-12:00
Strategic approach for the PEGylation of GLP-1 analogues
Kang Choon Lee, Sungkyunkwan University, South Korea
12:00-12:30
“Green” nanomedicine using “cage” nanoassemblies
Ruxandra Gref, University of Paris-Sud, France
12:30-14:00
Lunch
14:00-14:30
Polymeric nanoparticles for targeted drug delivery
Wim E. Hennink, Utrecht University, The Netherlands
14:30-15:00
Noninvasive in vivo monitoring of Nano-DDS: distribution, stimulus-sensitive release and therapeutic efficiency
Karsten Maeder, Martin-Luther - University of Halle, Germany
15:00-15:30
Nanodrugs: pharmacokinetics and safety
Satomi Onoue, University of Shizuoka, Japan
15:30-15:45
Coffee Break
15:45-16:15
Dissolution perspectives for nanotechnology products
Susan D’Souza, Sunovion Pharm Inc., United States
16:15-16:45
Non-toxic solvent-based nanoparticle engineering for drug delivery
Alf Lamprecht, University of Bonn, Germany
16:45-17:00
Oral Presentation-4
17:00-17:15
Oral Presentation-5
17:15-17:30
Oral Presentation-6
Hall B, September 9, 2014
09:15-09:45
Biotechnology and biosimilar products
Hüseyin Yılmaz, Turkish Medicines and Medical Devices Agency – TİTCK, Turkey
09:45-10:15
Biosimilars: challenges and opportunities
Filiz Öner, Hacettepe University, Turkey
10:15-10:45
Biotech product development, manufacturing and analytical technology
Anthony Mire-Sluis, Amgen Inc., United States
10:45-11:00
Coffee Break
11:00-11:30
Biobetter : the past and the future of the long-acting drug
Young-Chul Sung, Pohang University of Science and Technology, South Korea
11:30-12:00
Biosimilars and noncomparables
Sundar Ramanan, Amgen Inc., United States
12:00-12:30
Manufacturing of vaccines - new trends
Tom Sam, Merck Sharp & Dohme (R.), The Netherlands
12:30-14:00
Lunch
14:00-14:30
Analysis, quality control and methods for determining counterfeit drug products in Turkey
Yücel Dener, Turkish Medicines and Medical Devices Agency-TİTCK, Turkey
14:30-15:00
Regulatory perspective of biotech products
Virginia Acha, Amgen Inc., United States
15:00-15:45
Biosimilars: Turkish regulatory aspect
R. Neslihan Gürsoy, Hacettepe University, Turkey
15:45-16:00
Coffee Break
16:00-16:30
Focus on biosimilar development
İrem Yenice, Sanovel Pharmaceuticals, Turkey
16:30-16:50
Current status and future directions of biotechnological and biosimilar drugs in Turkey
Hasan Ersin Zeytin, Pharmaceutical Manufacturers Association of Turkey - İEİS, Turkey / Nobel Pharma, Turkey
16:50-17:10
Biotechnological drug manufacturing and effects to Turkish economy
Cem Koçak, Pharmaceutical Industry Association of Turkey- TİSD, Turkey
7
Hall A, September 10, 2014
8
08:30-08:45
Introduction and overview of drug-device combination products
Sema Çalış, Hacettepe University, Turkey
08:45-09:15
Medical devices and CE certification time course from the perspective of medical device regulations
Memnune Boşgelmez, Turkish Medicines and Medical Devices Agency - TİTCK, Turkey
09:15-09:45
Title to be announced
Cem F. Bozkurt, Alvimedica Medical Devices, Turkey
09:45-10:00
Coffee Break
10:00-10:30
Therapeutic ability of orthopaedic implant technology is challenging biologic repair by tissue engineering
Bülent Atilla, Hacettepe University, Turkey
10:30-11:00
CE marking – changing & evolving requirements
Gert Bos, BSI Healthcare, United Kingdom
11:00-11:30
New developmental and regulatory aspects of drug/device combination products
Tom Sam, Merck Sharp & Dohme (R.), The Netherlands
11:30-12:00
Title to be announced
Sabina L. Hoekstra-van den Bosch, Philips Healthcare, The Netherlands
12:00-14:00
Lunch
14:00-14:30
Ideal Inhaler device design and importance of inhaler device selection for clinicians
Can Öztürk, Gazi University, Turkey
14:30-15:00
The responsibility of stakeholders for safety of medical devices
Kemal Tekin, University of Turkish Aeronautical Association, Turkey
15:00-15:30
The challenge in medical devices from R&D to application: Adventure of a cardiovascular stent
Kemal Tekin, University of Turkish Aeronautical Association, Turkey
15:30-16:00
National academic R&D grants
Demet Daşkın, TÜBİTAK-The National and Technological Research Council of Turkey, Turkey
16:00-16:30
Closing Ceremony
Hall B, September 10, 2014
08:45-09:15
The Inhalation Products: Implementations of Turkish Ministry of Health Turkish Medicines and Medical Devices Agency
Fatma Bilgen Beldüz, Turkish Medicines and Medical Devices Agency – TİTCK, Turkey
09:15-09:45
Prediction of aerosol delivery from pharmaceutical dry powder inhalers
Anthony J. Hickey, Research Triangle Institute, United States
09:45-10:15
Marketing authorization of dry powder inhalers
Anne Gayot, University of Lille, France
10:15-10:45
Understanding powder processing: the key to inhalation drug product development
Hartwig Steckel, Christian Albrecht University of Kiel, Germany
10:45-11:00
Coffee Break
11:00-11:30
cGMP for DPI Products : How to ensure prevention of cross-contamination
Oliver Schlaefli, Novartis, Switzerland
11:30-12:00
Drug nanoparticles: Production, dissolution, and pulmonary drug delivery
Philip Chi Lip Kwok, The University of Hong Kong, Hong Kong
12:00-12:30
Current and future DPI products
Farhad Farshi, Pharmaceutical Manufacturers Association of Turkey- İEİS, Turkey / Abdi İbrahim Pharmaceuticals, Turkey
12:30-14:00
Lunch
9
10
11
12
13
14
15